People · Operator

Michael Sheffery

Named in public records as an officer, director or promoter · active 2009–2009 · Pharmaceuticals

1
Companies
1
Filings
$30.5M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.)PharmaceuticalsSeries A$30.5M$334.7M2009
Operator network

Michael Sheffery at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Robert Nelsen · 22 companies · 1 sharedRobert NelsenKristina Burow · 16 companies · 1 sharedKristina BurowAmir Nashat · 14 companies · 1 sharedAmir NashatRobert Nelson · 7 companies · 1 sharedRobert NelsonDoug Cole · 6 companies · 1 sharedDoug ColeFaheem Hasnain · 5 companies · 1 sharedFaheem HasnainPAUL Grayson · 5 companies · 1 sharedPAUL GraysonSheila Gujrathi · 5 companies · 1 sharedSheila GujrathiWilliam Rastetter · 4 companies · 1 sharedWilliam RastetterJames Schmidt · 3 companies · 1 sharedJames SchmidtMarcus Boehm · 3 companies · 1 sharedMarcus BoehmRaymond Stevens · 3 companies · 1 sharedRaymond StevensChrysa Mineo · 2 companies · 1 sharedChrysa MineoEd Torres · 1 companies · 1 sharedEd TorresRobert Peach · 1 companies · 1 sharedRobert PeachReceptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) · $30.5M raisedReceptos, Inc. (f.k.a…Michael ShefferyMS
Michael Sheffery Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Michael Sheffery on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Robert Nelsen122
Kristina Burow116
Amir Nashat114
Robert Nelson17
Doug Cole16
Sheila Gujrathi15
PAUL Grayson15
Faheem Hasnain15
William Rastetter14
Marcus Boehm13
Raymond Stevens13
James Schmidt13
Chrysa Mineo12
Ed Torres11
Robert Peach11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.